The GLOBOCAN database revealed that there were 544,100 esophageal cancer deaths and 604,100 new cases worldwide in 2020, translating to age-standardized incidence and mortality rates of 6.3 and 5.6 per 100,000, respectively. Interestingly, men account for about 70% of instances, and there is a significant gender disparity in frequency worldwide, with men being impacted two to five times more frequently than women.
The Esophageal Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights into the drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for esophageal cancer. The report includes the analysis of over 50 pipeline drugs and 15+ companies. The esophageal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from esophageal cancer. The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing product development activities related to esophageal cancer are covered. Moreover, esophageal cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Esophageal cancer develops at the esophagus, the lengthy tube that connects the throat to the stomach. It can spread to other areas of the body and usually begins in the cells that line the esophagus. The common categories of the disease include squamous cell carcinoma and adenocarcinoma. This cancer is more common in men (particularly those aged above 50) and people with a history of alcohol or tobacco use. Patients suffering from the condition may experience symptoms like chest pain, trouble swallowing, and inexplicable weight loss. Esophageal cancer treatment is more difficult because it is frequently discovered at an advanced stage.
The patient's health, the disease's location, and its stage all affect how esophageal cancer is treated. Endoscopic techniques can be used to remove tiny tumors in early-stage malignancies. Localized cancer frequently results in surgery, such as an esophagectomy, which involves removing all or part of the esophagus. Before or after surgery, chemotherapy and radiation therapy are frequently utilized to reduce tumor size or eradicate any cancer cells that may still be present. Chemotherapy, radiation, and targeted treatments like immunotherapy may be used in conjunction to treat advanced-stage cancer to control symptoms and extend survival. Regular follow-ups are required for monitoring after treatment. A large number of clinical trials for esophageal cancer has influenced the pipeline landscape positively.
This section of the report covers the analysis of esophageal cancer drug candidates based on several segmentations including:
By Phase
By Molecule Type
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for esophageal cancer with 38 pipeline drugs in phase I.
The drug molecule categories covered under esophageal cancer pipeline report include oligonucleotides, peptides and small molecules. Studies reveal that targeted monoclonal antibodies have been highly effective in the management of esophageal cancer. The esophageal cancer report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for esophageal cancer.
The EMR report for the esophageal cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed esophageal cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in esophageal cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
The trial studies the safety and efficacy of Pembrolizumab in patient suffering from esophageal cancer. The trial is sponsored by Merck Sharp & Dohme LLC and is currently under phase II.
The study evaluates the efficacy and safety of lomvastomig for esophageal cancer treatment. The trial is sponsored by F. Hoffmann-La Roche and is currently under phase II.
The trial, sponsored by Novartis Pharmaceuticals and currently in phase III. It evaluates the efficacy and tolerability of Lapatinib in patients with esophageal cancer.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Esophageal Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for esophageal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into esophageal cancer collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Molecule Type |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share